NEEDHAM, Mass.--(BUSINESS WIRE)--Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that the Company’s first antibody-drug conjugate (ADC) product candidate, CDX-011 (formerly CR011-vcMMAE), for the treatment of locally advanced or metastatic breast cancer will be the subject of a poster presentation at the 2009 San Antonio Breast Cancer Symposium. Poster #6096, “A Phase I/II Study of CR011-VcMMAE, an Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Breast Cancer,” will include safety, tolerability and efficacy data. It is scheduled for presentation during Poster Session 6 in Exhibit Halls A-B from 7:00 a.m. to 9:00 a.m. CST on Sunday, December 13, 2009 at the Henry B. Gonzalez Convention Center in San Antonio, TX.
